NO145691C - Analogifremgangsmaate til fremstilling av terapeutisk virksomme decapeptidamider - Google Patents

Analogifremgangsmaate til fremstilling av terapeutisk virksomme decapeptidamider

Info

Publication number
NO145691C
NO145691C NO750763A NO750763A NO145691C NO 145691 C NO145691 C NO 145691C NO 750763 A NO750763 A NO 750763A NO 750763 A NO750763 A NO 750763A NO 145691 C NO145691 C NO 145691C
Authority
NO
Norway
Prior art keywords
decapeptidamides
preparation
therapeutically effective
analogy procedure
analogy
Prior art date
Application number
NO750763A
Other languages
English (en)
Norwegian (no)
Other versions
NO145691B (no
NO750763L (de
Inventor
Masahiko Fujino
Tsunehiko Fukuda
Susuma Shinagawa
Original Assignee
Takeda Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Chemical Industries Ltd filed Critical Takeda Chemical Industries Ltd
Publication of NO750763L publication Critical patent/NO750763L/no
Publication of NO145691B publication Critical patent/NO145691B/no
Publication of NO145691C publication Critical patent/NO145691C/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10Tetrapeptides
    • C07K5/1002Tetrapeptides with the first amino acid being neutral
    • C07K5/1005Tetrapeptides with the first amino acid being neutral and aliphatic
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/23Luteinising hormone-releasing hormone [LHRH]; Related peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00Peptide or protein sequence
    • Y10S930/01Peptide or protein sequence
    • Y10S930/13Luteinizing hormone-releasing hormone; related peptides
NO750763A 1974-03-08 1975-03-07 Analogifremgangsmaate til fremstilling av terapeutisk virksomme decapeptidamider NO145691C (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2744274A JPS5726506B2 (de) 1974-03-08 1974-03-08

Publications (3)

Publication Number Publication Date
NO750763L NO750763L (de) 1975-09-09
NO145691B NO145691B (no) 1982-02-01
NO145691C true NO145691C (no) 1982-05-12

Family

ID=12221217

Family Applications (1)

Application Number Title Priority Date Filing Date
NO750763A NO145691C (no) 1974-03-08 1975-03-07 Analogifremgangsmaate til fremstilling av terapeutisk virksomme decapeptidamider

Country Status (18)

Country Link
US (1) US3972859A (de)
JP (1) JPS5726506B2 (de)
AT (1) AT348693B (de)
BE (1) BE826430A (de)
CA (1) CA1072953A (de)
CH (1) CH615661A5 (de)
CS (1) CS186284B2 (de)
DE (1) DE2509783C2 (de)
DK (1) DK149862C (de)
ES (1) ES435405A1 (de)
FI (1) FI60859C (de)
FR (1) FR2262995B1 (de)
GB (1) GB1498048A (de)
HU (1) HU174077B (de)
NL (1) NL181658C (de)
NO (1) NO145691C (de)
SE (1) SE420718B (de)
ZA (1) ZA751306B (de)

Families Citing this family (106)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2438350C3 (de) * 1974-08-09 1979-06-13 Hoechst Ag, 6000 Frankfurt Peptide mit starker LH-RH/FSH-RH-Wirkung, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Zubereitungen
AU497512B2 (en) * 1975-04-15 1978-12-14 Ici Australia Limited Nona and deca-peptides
US4215038A (en) * 1978-10-16 1980-07-29 The Salk Institute For Biological Studies Peptides which inhibit gonadal function
US4234571A (en) * 1979-06-11 1980-11-18 Syntex (U.S.A.) Inc. Nonapeptide and decapeptide derivatives of luteinizing hormone releasing hormone
US4318905A (en) * 1980-06-23 1982-03-09 Syntex (U.S.A.) Inc. Nonapeptide and decapeptide agonists of luteinizing hormone releasing hormone containing heterocyclic amino acid residues
ZA815447B (en) * 1980-08-29 1982-08-25 Salk Inst For Biological Studi Peptides affecting gonadal function
US4675189A (en) * 1980-11-18 1987-06-23 Syntex (U.S.A.) Inc. Microencapsulation of water soluble active polypeptides
PH19942A (en) * 1980-11-18 1986-08-14 Sintex Inc Microencapsulation of water soluble polypeptides
IE52535B1 (en) * 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
BR8208035A (pt) * 1981-12-28 1983-11-22 Beckman Instruments Inc Peptideos sinteticos tendo atividade liberadora de hormonio do crescimento da pituitaria
JPS58125819U (ja) * 1982-02-19 1983-08-26 名伸電機株式会社 積算電力量計用パツキン
US4581169A (en) * 1982-12-21 1986-04-08 Syntex (U.S.A.) Inc. Nona-peptide and deca-peptide analogs of LHRH, useful as LHRH antagonists
US4481190A (en) * 1982-12-21 1984-11-06 Syntex (U.S.A.) Inc. Nonapeptide and decapeptide analogs of LHRH useful as LHRH antagonists
US4667014A (en) * 1983-03-07 1987-05-19 Syntex (U.S.A.) Inc. Nonapeptide and decapeptide analogs of LHRH, useful as LHRH antagonists
US4663435A (en) * 1982-12-06 1987-05-05 Merck & Co., Inc. Bridged cyclic hexapeptide somatostatin analogs
US4581168A (en) * 1983-02-21 1986-04-08 Sanofi Synthesis of hpGRF (Somatocrinin) in liquid phase and intermediate peptides
US4530920A (en) * 1983-11-07 1985-07-23 Syntex (U.S.A.) Inc. Nonapeptide and decapeptide analogs of LHRH, useful as LHRH agonist
US4897268A (en) * 1987-08-03 1990-01-30 Southern Research Institute Drug delivery system and method of making the same
JP2653255B2 (ja) 1990-02-13 1997-09-17 武田薬品工業株式会社 長期徐放型マイクロカプセル
CA2050425A1 (en) 1990-09-03 1992-03-04 Yoshiaki Uda Pharmaceutical composition and its mucous use
ZA918168B (en) 1990-10-16 1993-04-14 Takeda Chemical Industries Ltd Prolonged release preparation and polymers thereof.
US6011068A (en) * 1991-08-23 2000-01-04 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
US5688938A (en) * 1991-08-23 1997-11-18 The Brigham & Women's Hospital, Inc. Calcium receptor-active molecules
US5763569A (en) * 1991-08-23 1998-06-09 The Brigham And Women's Hospital, Inc Calcium receptor-active molecules
US6031003A (en) * 1991-08-23 2000-02-29 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
US6313146B1 (en) 1991-08-23 2001-11-06 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
US5518730A (en) * 1992-06-03 1996-05-21 Fuisz Technologies Ltd. Biodegradable controlled release flash flow melt-spun delivery system
EP0582459B1 (de) 1992-08-07 1998-01-07 Takeda Chemical Industries, Ltd. Herstellung von Mikrokapseln, die wasserlösliche Arzneimittel enthalten
US5962314A (en) * 1993-02-23 1999-10-05 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
US20040259113A1 (en) * 1993-07-22 2004-12-23 Mayo Foundation For Medical Education And Research, Hybritech Incorporated Method for detection of metastatic prostate cancer
US6103237A (en) * 1993-07-22 2000-08-15 Hybritech Incorporated Stable variant hK2 polypeptide
US5516639A (en) * 1993-07-22 1996-05-14 Mayo Foundation For Medical Education And Research Antibodies specific for human prostate glandular kallkrein
DE69508985T2 (de) * 1994-02-21 1999-08-19 Takeda Chemical Industries Ltd Polyester Matrix für eine pharmazeutische Zusammensetzung mit verzögerter Freigabe
JPH10500294A (ja) * 1994-05-10 1998-01-13 マヨ ファウンデーション フォー メディカル エデュケーション アンド リサーチ 組換え型hk2ポリペプチド
US6117455A (en) 1994-09-30 2000-09-12 Takeda Chemical Industries, Ltd. Sustained-release microcapsule of amorphous water-soluble pharmaceutical active agent
EP1553078A1 (de) 1994-10-21 2005-07-13 Nps Pharmaceuticals, Inc. Kalzium-Rezeptor aktive Verbindungen
US5837281A (en) 1995-03-17 1998-11-17 Takeda Chemical Industries, Ltd. Stabilized interface for iontophoresis
CA2192773C (en) 1995-12-15 2008-09-23 Hiroaki Okada Production of sustained-release preparation for injection
CA2192782C (en) 1995-12-15 2008-10-14 Nobuyuki Takechi Production of microspheres
DK0907631T3 (da) 1996-05-01 2003-09-22 Nps Pharma Inc Uorganiske ionreceptoraktive forbindelser
CA2208336A1 (en) * 1996-06-20 1997-12-20 Hisamitsu Pharmaceuticals Co., Inc. A device structure for iontophoresis
US6479263B1 (en) 1996-11-14 2002-11-12 Baylor College Of Medicine Method for detection of micrometastatic prostate cancer
US6235486B1 (en) 1997-06-20 2001-05-22 Mayo Foundation For Medical Education & Research Method for detection of breast cancer
US6737408B1 (en) 1997-08-07 2004-05-18 University Of Cincinnati Compounds for control of appetite, blood pressure, cardiovascular response, libido, and circadian rhythm
US6087128A (en) * 1998-02-12 2000-07-11 Ndsu Research Foundation DNA encoding an avian E. coli iss
US8609614B2 (en) * 1998-07-22 2013-12-17 Vanderbilt University GBS toxin receptor compositions and methods of use
US6803448B1 (en) * 1998-07-22 2004-10-12 Vanderbilt University GBS toxin receptor
US6339062B1 (en) 1998-11-23 2002-01-15 Inkine Pharmaceutical Company, Inc. Retroinverso polypeptides that mimic or inhibit thrombospondin activity
US20050020524A1 (en) * 1999-04-15 2005-01-27 Monash University Hematopoietic stem cell gene therapy
US20040259803A1 (en) * 1999-04-15 2004-12-23 Monash University Disease prevention by reactivation of the thymus
US20040258672A1 (en) * 1999-04-15 2004-12-23 Monash University Graft acceptance through manipulation of thymic regeneration
US20040265285A1 (en) * 1999-04-15 2004-12-30 Monash University Normalization of defective T cell responsiveness through manipulation of thymic regeneration
AUPR074500A0 (en) * 2000-10-13 2000-11-09 Monash University Treatment of t cell disorders
US20070274946A1 (en) * 1999-04-15 2007-11-29 Norwood Immunoloty, Ltd. Tolerance to Graft Prior to Thymic Reactivation
US20040241842A1 (en) * 1999-04-15 2004-12-02 Monash University Stimulation of thymus for vaccination development
US20050042679A1 (en) * 1999-04-15 2005-02-24 Monash University Diagnostic indicator of thymic function
AU783087B2 (en) * 1999-08-06 2005-09-22 Genentech Inc. Peptide antagonists of factor VIIA
US6407211B1 (en) 1999-12-17 2002-06-18 Mayo Foundation For Medical Education And Research Chimeric natriuretic peptides
US20050287153A1 (en) * 2002-06-28 2005-12-29 Genentech, Inc. Serum albumin binding peptides for tumor targeting
CA2921260A1 (en) * 1999-12-24 2001-06-28 Genentech, Inc. Methods and compositions for prolonging elimination half-times of bioactive compounds
US20060228364A1 (en) * 1999-12-24 2006-10-12 Genentech, Inc. Serum albumin binding peptides for tumor targeting
US20040001827A1 (en) * 2002-06-28 2004-01-01 Dennis Mark S. Serum albumin binding peptides for tumor targeting
EP1757701A1 (de) 1999-12-24 2007-02-28 Genentech, Inc. Verfahren und Zusammensetzungen zur Verlängerung der Halbzeiten der Entfernung von biowirksamen Verbindungen
US20060088512A1 (en) * 2001-10-15 2006-04-27 Monash University Treatment of T cell disorders
US7164002B2 (en) 2002-02-06 2007-01-16 Genentech, Inc. FVIIa antagonists
US7968080B2 (en) * 2003-08-20 2011-06-28 The Regents Of The University Of California Somatostatin analogs with inhibitory activity to growth hormone release
JP4621674B2 (ja) * 2003-09-18 2011-01-26 レイベン バイオテクノロジーズ,インコーポレイティド Kid3およびkid3に結合するkid3抗体
US20080279812A1 (en) * 2003-12-05 2008-11-13 Norwood Immunology, Ltd. Disease Prevention and Vaccination Prior to Thymic Reactivation
JP4390568B2 (ja) * 2004-01-19 2009-12-24 富士通株式会社 遅延測定システム
US7572895B2 (en) * 2004-06-07 2009-08-11 Raven Biotechnologies, Inc. Transferrin receptor antibodies
BRPI0516577A (pt) * 2004-10-05 2008-09-16 Genentech Inc agentes terapêuticos com toxicidade diminuìda
EP1846767B1 (de) 2005-01-12 2012-06-06 MacroGenics West, Inc. Kid31 und daran bindende antikörper
WO2006083852A2 (en) * 2005-01-31 2006-08-10 Raven Biotechnologies, Inc. Luca2 and antibodies that bind thereto
WO2006084078A2 (en) * 2005-02-02 2006-08-10 Raven Biotechnologies, Inc. Jam-3 and antibodies that bind thereto
EP1841794B1 (de) 2005-02-02 2013-11-20 MacroGenics West, Inc. Adam-9-modulatoren
JP5328156B2 (ja) 2005-02-03 2013-10-30 マクロジェニックス ウエスト, インコーポレイテッド オンコスタチンmレセプターに対する抗体
EP1790656A1 (de) * 2005-11-25 2007-05-30 Nanokem S.A. Lösungsphasesynthese von Leuprolid
US20070197445A1 (en) * 2006-01-18 2007-08-23 University Of Cincinnati Compounds for control of appetite
US7718774B2 (en) * 2006-11-08 2010-05-18 Macrogenics, Inc. TES7 and antibodies that bind thereto
EP2421549B1 (de) 2009-04-20 2013-06-12 Allergan, Inc. Seiden-fibroin-hydrogele und ihre verwendungen
PL219569B1 (pl) * 2010-02-19 2015-05-29 Peptaderm Spółka Z Ograniczoną Odpowiedzialnością Cykliczne tetrapeptydy i ich zastosowanie
ME03447B (de) 2010-03-04 2020-01-20 Macrogenics Inc Mit b7-h3 reagierende antikörper, immunologisch wirkende fragmente davon und verwendungen davon
US8802091B2 (en) 2010-03-04 2014-08-12 Macrogenics, Inc. Antibodies reactive with B7-H3 and uses thereof
MX369220B (es) 2011-05-21 2019-10-31 Macrogenics Inc Moleculas que enlazan cd3 capaces de enlazar a cd3 humano y no humano.
EP2557163A1 (de) 2011-08-12 2013-02-13 SymbioGruppe GmbH & Co KG Bakteriell gebildetes Mikrocin S, ein neues antimikrobielles Peptid, das gegen pathogene Mikroorganismen wirkt, z.B. enterohämorrhagisches Eschericha Coli (EHEC)
BR112014004014A2 (pt) 2011-08-23 2020-10-27 President And Fellows Of Harvard College partículas de peptídeos e seus usos
JP2014525439A (ja) 2011-08-30 2014-09-29 メイヨ・ファウンデーション・フォー・メディカル・エデュケーション・アンド・リサーチ ナトリウム利尿ポリペプチド
WO2013103896A1 (en) 2012-01-06 2013-07-11 Mayo Foundation For Medical Education And Research Treating cardiovascular or renal diseases
US9487587B2 (en) 2013-03-05 2016-11-08 Macrogenics, Inc. Bispecific molecules that are immunoreactive with immune effector cells of a companion animal that express an activating receptor and cells that express B7-H3 and uses thereof
SG11201507424WA (en) 2013-03-14 2015-10-29 Macrogenics Inc Bispecific molecules that are immunoreactive with immune effector cells that express an activating receptor
US20160106813A1 (en) 2013-03-29 2016-04-21 Centre National De La Recherche Schientifique (Cnrs) Cgrp receptor agonist for hiv treatment or prevention
NZ726520A (en) 2014-05-29 2018-12-21 Macrogenics Inc Tri-specific binding molecules that specifically bind to multiple cancer antigens and methods of use thereof
CA2963991A1 (en) 2014-09-29 2016-04-07 Duke University Bispecific molecules comprising an hiv-1 envelope targeting arm
TWI773646B (zh) 2015-06-08 2022-08-11 美商宏觀基因股份有限公司 結合lag-3的分子和其使用方法
HRP20211645T1 (hr) 2015-07-30 2022-02-04 Macrogenics, Inc. Molekule za vezanje pd-1 i postupci za njihovu uporabu
KR20180084772A (ko) 2015-10-08 2018-07-25 마크로제닉스, 인크. 암 치료를 위한 조합 치료법
JP7227007B2 (ja) 2015-12-02 2023-02-21 ストサイエンシス, インコーポレイテッド グリコシル化btla(b-及びt-リンパ球減弱因子)に特異的な抗体
BR112018011781A2 (pt) 2015-12-14 2018-12-04 Macrogenics Inc molécula biespecífica possuindo um ou mais sítios de ligação a epítopo capazes de ligação imunoespecífica a (um) epítopo(s) de pd-1 e um ou mais sítios de ligação a epítopo capazes de ligação imunoespecífica a (um) epítopo(s) de ctla-4, e composição farmacêutica
JP7002467B2 (ja) 2016-04-15 2022-01-20 マクロジェニクス,インコーポレーテッド 新規のb7‐h3結合分子、その抗体薬物コンジュゲート、及びその使用方法
US10111929B1 (en) 2017-04-07 2018-10-30 Ez Ip, Llc Growth hormone releasing factor analogs and uses
US20220411511A1 (en) 2019-09-26 2022-12-29 Stcube & Co. Antibodies specific to glycosylated ctla-4 and methods of use thereof
JP2022552282A (ja) 2019-10-09 2022-12-15 エスティーキューブ アンド カンパニー グリコシル化lag3に対して特異的な抗体およびその使用方法
US11596665B2 (en) 2020-06-23 2023-03-07 Chanda Zaveri Skin lightening formulations
US11951203B2 (en) 2020-08-26 2024-04-09 Chanda Zaveri Deep wrinkle vanishing compositions
US11793746B2 (en) 2020-10-01 2023-10-24 Chanda Zaveri Intense skin hydration systems and methods
US20220110852A1 (en) 2020-10-14 2022-04-14 Chanda Zaveri Pigment Stabilizers

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3835108A (en) * 1972-02-15 1974-09-10 American Home Prod Process for preparing the releasing hormone of luteinizing hormone(lh)and of follicle stimulating hormone(fsh),salts and compositions thereof,and intermediates therefor
US3896104A (en) * 1974-05-22 1975-07-22 American Home Prod P-glu-his-trp-ser-tyr-d-lys-leu-arg-pro-gly-nh' 2 'and intermediates

Also Published As

Publication number Publication date
DE2509783C2 (de) 1983-02-17
CS186284B2 (en) 1978-11-30
DK149862C (da) 1987-06-15
FI750682A (de) 1975-09-09
NL181658C (nl) 1987-10-01
US3972859A (en) 1976-08-03
HU174077B (hu) 1979-10-28
FI60859B (fi) 1981-12-31
NO145691B (no) 1982-02-01
CA1072953A (en) 1980-03-04
JPS50121277A (de) 1975-09-23
FR2262995A1 (de) 1975-10-03
CH615661A5 (de) 1980-02-15
DK92775A (de) 1975-09-09
NL7502564A (nl) 1975-09-10
SE7502520L (de) 1975-09-09
NO750763L (de) 1975-09-09
ATA138075A (de) 1978-07-15
ZA751306B (en) 1976-01-28
ES435405A1 (es) 1976-12-01
DK149862B (da) 1986-10-13
NL181658B (nl) 1987-05-04
JPS5726506B2 (de) 1982-06-04
DE2509783A1 (de) 1975-09-11
BE826430A (fr) 1975-09-08
FI60859C (fi) 1982-04-13
SE420718B (sv) 1981-10-26
AT348693B (de) 1979-02-26
AU7859475A (en) 1976-08-26
GB1498048A (en) 1978-01-18
FR2262995B1 (de) 1978-07-28

Similar Documents

Publication Publication Date Title
NO145691C (no) Analogifremgangsmaate til fremstilling av terapeutisk virksomme decapeptidamider
NO146200C (no) Analogifremgangsmaate til fremstilling av terapeutisk virksomme 16-oksygenerte prostansyrederivater
NO157933C (no) Analogifremgangsmaate for fremstilling av terapeutisk virksomme cefemforbindelser.
NO149106C (no) Analogifremgangsmaate for fremstilling av farmakologisk aktive benzcykloamider
NO145075C (no) Kontinuerlig fremgangsmaate til fremstilling av alkoksysilaner
SE7513085L (sv) Forfarande for framstellning av etrar
NO143796C (no) Analogifremgangsmaate til fremstilling av terapeutisk virksomme piperazinyliminorifamyciner
NO142303C (no) Analogifremgangsmaate til fremstilling av terapeutisk virksomme oksazolderivater
NO152509C (no) Analogifremgangsmaate til fremstilling av terapeutisk virksomme cephalosporinforbindelser
SE421209B (sv) Analogiforfarande for framstellning av tienobensodiazepiner
SE7506160L (sv) Forfarande for framstellning av n-cykloalkylmetyldekahydroisokinoline
NO141755C (no) Analogifremgangsmaate til fremstilling av terapeutisk virksomme dotriacontapeptidamider
NO146022C (no) Analogifremgangsmaate til fremstilling av terapeutisk virksomme benzofenonderivater
NO141894C (no) Analogifremgangsmaate for fremstilling av farmakologisk aktive pyridobenzodiazepinoner
NO141262C (no) Analogifremgangsmaate til fremstilling av terapeutisk virksomme tripeptider
NO143625C (no) Analogifremgangsmaate for fremstilling av 2-metoksy-benzamider
NO144604C (no) Analogifremgangsmaate til fremstilling av terapeutisk virksomme histidinderivater
SE411453B (sv) Forfarande for framstellning av 3-fluorcefalosporiner
SE403477B (sv) Forfarande for famstellning av substituerade indoleniner
NO142907C (no) Analogifremgangsmaate til fremstilling av terapeutisk virksomme fenylalkylaminer
SE7511801L (sv) Forfarande for framstellning av ympsampolymerisat
NO153221C (no) Analogifremgangsmaate for fremstilling av terapeutisk virksomme 6-metoksy-alfa-karboksypenicilliner.
NO143501C (no) Analogifremgangsmaate til fremstilling av terapeutisk virksom benzopyranforbindelse
NO144741C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive tiopyrano-pyrazoler
NO145982C (no) Analogifremgangsmaate til fremstilling av terapeutisk virksomme monokromon-forbindelser